Yousif Capital Management LLC Has $530,000 Stock Position in Xencor, Inc. (NASDAQ:XNCR)

Yousif Capital Management LLC trimmed its position in Xencor, Inc. (NASDAQ:XNCR) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,947 shares of the biopharmaceutical company’s stock after selling 1,132 shares during the quarter. Yousif Capital Management LLC’s holdings in Xencor were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of XNCR. CWM LLC lifted its stake in shares of Xencor by 498.7% in the fourth quarter. CWM LLC now owns 1,377 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 1,147 shares during the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Xencor in the third quarter worth $31,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Xencor by 95.5% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,548 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 756 shares during the last quarter. Signaturefd LLC raised its stake in Xencor by 367.7% during the 4th quarter. Signaturefd LLC now owns 1,464 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,151 shares during the last quarter. Finally, Allworth Financial LP raised its stake in Xencor by 29,487.5% during the 4th quarter. Allworth Financial LP now owns 2,367 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 2,359 shares during the last quarter.

Insider Activity

In related news, VP John R. Desjarlais sold 1,280 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the sale, the vice president now directly owns 186,433 shares in the company, valued at approximately $4,381,175.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, Director Kurt A. Gustafson sold 14,000 shares of Xencor stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $23.18, for a total value of $324,520.00. Following the completion of the transaction, the director now directly owns 6,007 shares of the company’s stock, valued at $139,242.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP John R. Desjarlais sold 1,280 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $23.50, for a total transaction of $30,080.00. Following the transaction, the vice president now owns 186,433 shares in the company, valued at approximately $4,381,175.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 101,351 shares of company stock worth $2,152,417. Insiders own 5.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Piper Sandler reiterated a “neutral” rating and set a $24.00 target price (down from $37.00) on shares of Xencor in a research note on Wednesday, February 28th. Mizuho cut their target price on shares of Xencor from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 22nd. BTIG Research cut their target price on shares of Xencor from $56.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, April 16th. Royal Bank of Canada reiterated an “outperform” rating and set a $32.00 target price on shares of Xencor in a research note on Wednesday, February 28th. Finally, BMO Capital Markets cut their target price on shares of Xencor from $38.00 to $34.00 and set an “outperform” rating for the company in a research note on Wednesday, February 28th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $24.11 on Monday. Xencor, Inc. has a 52-week low of $16.49 and a 52-week high of $28.96. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.36 and a quick ratio of 7.36. The business has a fifty day moving average of $21.88 and a two-hundred day moving average of $20.50.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.36 by ($0.67). The firm had revenue of $44.70 million for the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative return on equity of 18.67%. The company’s revenue for the quarter was up 106.9% on a year-over-year basis. During the same period in the prior year, the business earned ($0.20) earnings per share. As a group, research analysts forecast that Xencor, Inc. will post -3.25 EPS for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.